A map of the PPARα transcription regulatory network for primary human hepatocytes.

Nuclear receptor activation in liver leads to coordinated alteration of the expression of multiple gene products with attendant phenotypic changes of hepatocytes. Peroxisome proliferators including endogenous fatty acids, environmental chemicals, and drugs induce a multi-enzyme metabolic response that affects lipid and fatty acid processing. We studied the signaling network for the peroxisome proliferator-associated receptor alpha (PPARα) in primary human hepatocytes using the selective PPARα ligand, GW7647. We measured gene expression over multiple concentrations and times and conducted ChIP-seq studies at 2 and 24h to assess genomic binding of PPARα. Over all treatments there were 192 genes differentially expressed. Of these only 51% showed evidence of PPARα binding-either directly at PPARα response elements or via alternative mechanisms. Almost half of regulated genes had no PPARα binding. We then developed two novel bioinformatics methods to visualize the dose-dependent activation of both the transcription factor circuitry for PPARα and the downstream metabolic network in relation to functional annotation categories. Available databases identified several key transcription factors involved with the non-genomic targets after GW7647 treatment, including SP1, STAT1, ETS1, ERα, and HNF4α. The linkage from PPARα binding through gene expression likely requires intermediate protein kinases to activate these transcription factors. We found enrichment of functional annotation categories for organic acid metabolism and cell lipid metabolism among the differentially expressed genes. Lipid transport processes showed enrichment at the highest concentration of GW7647 (10 μM). While our strategy for mapping transcriptional networks is evolving, these approaches are necessary in moving from toxicogenomic methods that derive signatures of activity to methods that establish pathway structure, showing the coordination of the activated nuclear receptor with other signaling pathways.

[1]  Philippe Lefebvre,et al.  Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .

[2]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[3]  Yi-Chun Lu,et al.  Co-regulation of Tissue-specific Alternative Human Carnitine Palmitoyltransferase Iβ Gene Promoters by Fatty Acid Enzyme Substrate* , 1998, The Journal of Biological Chemistry.

[4]  S. Lightman,et al.  Transcription factor interactions in genomic nuclear receptor function. , 2011, Epigenomics.

[5]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[6]  F. Hegardt,et al.  Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor* , 1998, The Journal of Biological Chemistry.

[7]  C. Rochette-Egly,et al.  MSK1 and Nuclear Receptors Signaling , 2013 .

[8]  M. Rao,et al.  Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. , 1976, Cancer research.

[9]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[10]  Anthony W. Norman,et al.  Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.

[11]  J. Pascussi,et al.  Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. , 2004, Gastroenterology.

[12]  M. Benito,et al.  Rosiglitazone and Retinoic Acid Induce Uncoupling Protein-1 (UCP-1) in a p38 Mitogen-activated Protein Kinase-dependent Manner in Fetal Primary Brown Adipocytes* , 2003, The Journal of Biological Chemistry.

[13]  J. Pascussi,et al.  Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites , 2004 .

[14]  Peter Tontonoz,et al.  Integration of metabolism and inflammation by lipid-activated nuclear receptors , 2008, Nature.

[15]  K. Griffin,et al.  Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator-activated Receptor α in HepG2 Cells* , 2001, The Journal of Biological Chemistry.

[16]  F. Gonzalez,et al.  PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. , 2008, Toxicology.

[17]  T. Willson,et al.  Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine , 2001 .

[18]  Yan Xie,et al.  Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. , 2010, Molecular endocrinology.

[19]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[20]  T. Ide,et al.  Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. , 2009, Biochemical pharmacology.

[21]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[22]  Philip Machanick,et al.  MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..

[23]  W. Wahli,et al.  PPARs Mediate Lipid Signaling in Inflammation and Cancer , 2008, PPAR research.

[24]  John Turk,et al.  Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver , 2009, Cell.

[25]  C. Wolf,et al.  Induction of cytochrome P-450 in cultured rat hepatocytes. The heterogeneous localization of specific isoenzymes using immunocytochemistry. , 1989, The Biochemical journal.

[26]  B. Ledwith,et al.  Peroxisome Proliferators Activate Extracellular Signal-regulated Kinases in Immortalized Mouse Liver Cells* , 1997, The Journal of Biological Chemistry.

[27]  Dominique Cansell,et al.  B Method , 2006, The Seventeen Provers of the World.

[28]  J. Reddy,et al.  Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens , 1980, Nature.

[29]  Michael Müller,et al.  Review Peroxisome proliferator-activated receptor a target genes , 2004 .

[30]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[31]  R. Cattley,et al.  Peroxisome Proliferators and Receptor-Mediated Hepatic Carcinogenesis , 2004, Toxicologic pathology.

[32]  F. Bermúdez-Silva,et al.  Rapid non-genomic regulation of Ca2+ signals and insulin secretion by PPAR alpha ligands in mouse pancreatic islets of Langerhans. , 2008, The Journal of endocrinology.

[33]  Jianming Xu,et al.  Coactivators in PPAR-Regulated Gene Expression , 2010, PPAR research.

[34]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[35]  J. Corton,et al.  Gene Profiling in the Livers of Wild-type and PPARα-Null Mice Exposed to Perfluorooctanoic Acid , 2008, Toxicologic pathology.

[36]  Richard M Myers,et al.  Genomic determination of the glucocorticoid response reveals unexpected mechanisms of gene regulation. , 2009, Genome research.

[37]  B. Thrall,et al.  The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. , 1999, Toxicology and applied pharmacology.

[38]  Steven G. Smith,et al.  The Effect of PPAR Agonists on the Migration of Mature and Immature Eosinophils , 2012, PPAR research.

[39]  James E Klaunig,et al.  PPARalpha agonist-induced rodent tumors: modes of action and human relevance. , 2003, Critical reviews in toxicology.

[40]  C. Chomienne,et al.  Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. , 2012, Cellular signalling.

[41]  M. Andersen,et al.  Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  J. McLauchlan,et al.  A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. , 2005, Biochimica et biophysica acta.

[43]  V K K Chatterjee,et al.  A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. , 2005, Endocrinology.

[44]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[45]  T. Willson,et al.  Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. , 2001, The Biochemical journal.

[46]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[47]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[48]  John H. White,et al.  Genome-wide identification of high-affinity estrogen response elements in human and mouse. , 2004, Molecular endocrinology.

[49]  Antoine M. van Oijen,et al.  Real-time single-molecule observation of rolling-circle DNA replication , 2009, Nucleic acids research.

[50]  P. D. de Groot,et al.  Profiling of promoter occupancy by PPARα in human hepatoma cells via ChIP-chip analysis , 2010, Nucleic acids research.

[51]  J. Auwerx,et al.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. , 1995, The Journal of clinical investigation.

[52]  W. Wilkison,et al.  Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.

[53]  V. Grachtchouk,et al.  Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function. , 2005, The Journal of biological chemistry.

[54]  D. Haro,et al.  An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A. , 2005, Journal of molecular biology.

[55]  L. Graves,et al.  Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation* , 2003, Journal of Biological Chemistry.

[56]  Margaret Warner,et al.  Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.

[57]  J. Reddy,et al.  Identification of a Peroxisome Proliferator-responsive Element Upstream of the Human Peroxisomal Fatty Acyl Coenzyme A Oxidase Gene (*) , 1996, The Journal of Biological Chemistry.

[58]  W. W. Nichols,et al.  Growth regulation by peroxisome proliferators: opposing activities in early and late G1. , 1996, Cancer research.

[59]  B. Komm,et al.  Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation , 2010, Molecular and Cellular Biology.

[60]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[61]  W. Wahli,et al.  The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment* , 2004, Journal of Biological Chemistry.

[62]  L. Sanderson,et al.  Comprehensive Analysis of PPARα-Dependent Regulation of Hepatic Lipid Metabolism by Expression Profiling , 2007, PPAR research.

[63]  M. Andersen,et al.  Ultrasensitive response motifs: basic amplifiers in molecular signalling networks , 2013, Open Biology.

[64]  Michael Müller,et al.  Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human , 2009, PloS one.

[65]  W. Wahli,et al.  Association with Coregulators Is the Major Determinant Governing Peroxisome Proliferator-activated Receptor Mobility in Living Cells* , 2007, Journal of Biological Chemistry.

[66]  Melvin E Andersen,et al.  Toxicity testing in the 21st century: bringing the vision to life. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[67]  V. Grachtchouk,et al.  Receptor-type Protein-tyrosine Phosphatase-κ Regulates Epidermal Growth Factor Receptor Function* , 2005, Journal of Biological Chemistry.

[68]  Hao Li,et al.  Determinants of Cell- and Gene-Specific Transcriptional Regulation by the Glucocorticoid Receptor , 2007, PLoS genetics.

[69]  Jun Ho Jeon,et al.  VDUP1 upregulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression , 2003, Oncogene.

[70]  B. Ledwith,et al.  Peroxisome proliferators activate growth regulatory pathways largely via peroxisome proliferator-activated receptor alpha-independent mechanisms. , 2002, Cellular signalling.

[71]  T. Kodama,et al.  Regulation of the human SLC25A20 expression by peroxisome proliferator-activated receptor alpha in human hepatoblastoma cells. , 2009, Biochemical and biophysical research communications.

[72]  J. Plutzky,et al.  PPARalpha in atherosclerosis and inflammation. , 2007, Biochimica et biophysica acta.

[73]  Zhiyong Guo,et al.  Novel Membrane-associated Androgen Receptor Splice Variant Potentiates Proliferative and Survival Responses in Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.

[74]  R. Roberts,et al.  Receptor-mediated hepatocarcinogenesis: role of hepatocyte proliferation and apoptosis. , 2002, Pharmacology & toxicology.

[75]  Mikael Bodén,et al.  MEME Suite: tools for motif discovery and searching , 2009, Nucleic Acids Res..